We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek
Read MoreHide Full Article
Key Takeaways
VRTX gains EU approval for Alyftrek to treat CF patients aged six and above with non-class I mutations.
Alyftrek offers once-daily dosing and potential benefits over Trikafta, including improved CFTR function.
Alyftrek sales reached $53.9M in Q1 2025, with management expecting stronger uptake in H2 2025.
Vertex Pharmaceuticals (VRTX - Free Report) announced that the European Commission has approved Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) for treating people with cystic fibrosis (“CF”) aged six years and above having at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (“CFTR”) gene.
Alyftrek is a combination of three drugs — vanzacaftor (a CFTR potentiator), deutivacaftor (a CFTR corrector) and tezacaftor.
The approval in the European Union was expected as the European Medical Agency’s Committee for Medicinal Products for Human Use rendered a positive opinion recommending approval of Alyftrek for people with CF aged six years and older in April.
Vertex’s fifth CFTR modulator therapy, Alyftrek (vanza triple), is a next-in-class triple combination regimen that was approved by the FDA in December 2024 for treating people with CF aged six years and older. The medicine was approved in the United Kingdom in March.
Regulatory filings seeking approval of Alyftrek are currently under review in Canada, Switzerland, Australia and New Zealand.
VRTX's Stock Performance
Year to date, shares of Vertex have risen 12.3% against the industry’s decline of 3.4%.
Image Source: Zacks Investment Research
Alyftrek, a Key Product in VRTX's CF Portfolio
Vertex holds a dominant position in the CF market. Its CF sales continue to grow, driven by the demand growth of the blockbuster drug, Trikafta/Kaftrio, in younger age groups. While in the near term, expansion to younger age groups should continue to drive CF sales growth, the launch of Alyftrek is expected to drive growth in the medium term.
Per management, Alyftrek has the potential to provide better patient benefits than Trikafta and become a new standard-of-care treatment in CF. It can possibly treat CF patients who have discontinued Trikafta or other Vertex CF medicines. The drug might also improve dosing (once daily), lower the royalty burden and extend patent protection from 2037 for Trikafta into 2039 for Alyftrek.
In two head-to-head studies, once-daily Alyftrek demonstrated non-inferiority to twice-daily Trikafta in combination with ivacaftor in improving ppFEV1 and showed superior reduction in sweat chloride levels, indicating greater improvement in CFTR function.
Despite the promising outlook, Alyftrek sales have been slower than expected in its first quarter of launch. During the first quarter of 2025, Alyftrek generated sales of $53.9 million. Management expects Alyftrek sales to pick up in the second half of 2025, as the majority of patients in the United States who are currently on Trikafta are expected to switch to Alyftrek.
Vertex is also evaluating Alyftrek in children with CF aged between two and five years.
In the past 60 days, estimates for Exelixis’ earnings per share have increased from $2.31 to $2.64 for 2025. During the same time, earnings per share estimates for 2026 have increased from $2.85 to $3.13. Year to date, shares of EXEL have rallied 31%.
EXEL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 48.60%.
In the past 60 days, estimates for Spero Therapeutics’ loss per share have narrowed from $2.32 to $1.43 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $1.98 to $1.15. Year to date, shares of SPRO have surged 181.6%.
SPRO’s earnings beat estimates in two of the trailing four quarters, while missing the same in the remaining two occasions, the average surprise being 8.29%.
In the past 60 days, estimates for Puma Biotechnology’s earnings per share have increased from 60 cents to 65 cents for 2025. During the same time, earnings per share estimates for 2026 have risen from 48 cents to 51 cents. Year to date, shares of PBYI have gained 17.7%.
PBYI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 171.43%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek
Key Takeaways
Vertex Pharmaceuticals (VRTX - Free Report) announced that the European Commission has approved Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) for treating people with cystic fibrosis (“CF”) aged six years and above having at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (“CFTR”) gene.
Alyftrek is a combination of three drugs — vanzacaftor (a CFTR potentiator), deutivacaftor (a CFTR corrector) and tezacaftor.
The approval in the European Union was expected as the European Medical Agency’s Committee for Medicinal Products for Human Use rendered a positive opinion recommending approval of Alyftrek for people with CF aged six years and older in April.
Vertex’s fifth CFTR modulator therapy, Alyftrek (vanza triple), is a next-in-class triple combination regimen that was approved by the FDA in December 2024 for treating people with CF aged six years and older. The medicine was approved in the United Kingdom in March.
Regulatory filings seeking approval of Alyftrek are currently under review in Canada, Switzerland, Australia and New Zealand.
VRTX's Stock Performance
Year to date, shares of Vertex have risen 12.3% against the industry’s decline of 3.4%.
Image Source: Zacks Investment Research
Alyftrek, a Key Product in VRTX's CF Portfolio
Vertex holds a dominant position in the CF market. Its CF sales continue to grow, driven by the demand growth of the blockbuster drug, Trikafta/Kaftrio, in younger age groups. While in the near term, expansion to younger age groups should continue to drive CF sales growth, the launch of Alyftrek is expected to drive growth in the medium term.
Per management, Alyftrek has the potential to provide better patient benefits than Trikafta and become a new standard-of-care treatment in CF. It can possibly treat CF patients who have discontinued Trikafta or other Vertex CF medicines. The drug might also improve dosing (once daily), lower the royalty burden and extend patent protection from 2037 for Trikafta into 2039 for Alyftrek.
In two head-to-head studies, once-daily Alyftrek demonstrated non-inferiority to twice-daily Trikafta in combination with ivacaftor in improving ppFEV1 and showed superior reduction in sweat chloride levels, indicating greater improvement in CFTR function.
Despite the promising outlook, Alyftrek sales have been slower than expected in its first quarter of launch. During the first quarter of 2025, Alyftrek generated sales of $53.9 million. Management expects Alyftrek sales to pick up in the second half of 2025, as the majority of patients in the United States who are currently on Trikafta are expected to switch to Alyftrek.
Vertex is also evaluating Alyftrek in children with CF aged between two and five years.
VRTX's Zacks Rank & Stocks to Consider
Vertex currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Exelixis (EXEL - Free Report) , Spero Therapeutics (SPRO - Free Report) and Puma Biotechnology (PBYI - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Exelixis’ earnings per share have increased from $2.31 to $2.64 for 2025. During the same time, earnings per share estimates for 2026 have increased from $2.85 to $3.13. Year to date, shares of EXEL have rallied 31%.
EXEL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 48.60%.
In the past 60 days, estimates for Spero Therapeutics’ loss per share have narrowed from $2.32 to $1.43 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $1.98 to $1.15. Year to date, shares of SPRO have surged 181.6%.
SPRO’s earnings beat estimates in two of the trailing four quarters, while missing the same in the remaining two occasions, the average surprise being 8.29%.
In the past 60 days, estimates for Puma Biotechnology’s earnings per share have increased from 60 cents to 65 cents for 2025. During the same time, earnings per share estimates for 2026 have risen from 48 cents to 51 cents. Year to date, shares of PBYI have gained 17.7%.
PBYI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 171.43%.